Pyrotinib plus trastuzumab and chemotherapy for HER2-positive early breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three drugs—pyrotinib, trastuzumab, and chemotherapy—to treat HER2-positive breast cancer that has not been treated before. HER2 is a protein found on some cancer cells; blocking it may help stop the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 65 years old
- You have invasive breast cancer confirmed by a pathologist, and it is HER2-positive (a specific protein marker on the cancer cells)
- Your cancer has not been treated with any chemotherapy, radiation, targeted therapy, or hormone therapy before
- Your cancer is stage II or III (early stage, not spread to distant parts of the body)
- Your heart, liver, and kidney function are adequate based on blood tests and heart imaging
- You are not pregnant, not breastfeeding, and willing to use contraception during and for 8 weeks after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
This trial tests whether giving a combination of two targeted drugs (pyrotinib and trastuzumab) along with standard chemotherapy before surgery can work better for HER2-positive breast cancer. It is for women whose cancer has not spread to distant organs and who have not yet had treatment for their cancer.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) as maintenance therapy to keep HER2-positive breast cancer that has spread under control. It is for women who have already received some first-line treatment and are stable enough to continue therapy.
This trial tests a targeted drug called pyrotinib for women with HER2-positive early or locally advanced breast cancer. It aims to see if adding this treatment before surgery improves outcomes.
This Phase 2 trial tests pyrotinib, a HER2-targeted cancer medicine, in people with high-risk, HER2-positive breast cancer after surgery. It aims to lower the chance the cancer comes back, especially when standard treatment did not fully clear the tumor.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.